key: cord-1030738-cbvdwn86
authors: Haider, Mohammad Z; Al-Mannai, Amna; Al-Sirhan, Sally; Elsabagh, Ahmed; Nasser, Nasser; Al-Quraishi, Noora; Ouda, Amr; Erradi, Khadija; Ashour, Anas A; Gupta, Ishita; Abdulmajeed, Jazeel; Al-Romaihi, Hamad E; Bansal, Devendra; Musa, Omran A H; Abd Farag, Elmoubasher Abu Baker; Al-Thani, Mohammed H J; Al Moustafa, Ala-Eddin
title: Impact of Smoking on COVID-19 Symptoms in Non-Vaccinated Patients: A Matched Observational Study from Qatar
date: 2022-03-17
journal: J Multidiscip Healthc
DOI: 10.2147/jmdh.s347130
sha: 3ce5a3d4d5ea87c582137b3d02818c68cc0fc821
doc_id: 1030738
cord_uid: cbvdwn86

PURPOSE: Predisposition to acute illness from COVID-19 is suggested to correlate with cigarette smoking as it augments the risk of developing cardiovascular and respiratory illnesses, including infections. However, the effects of smoking on COVID-19 symptoms are not well described and controversial. In this study, we aim to explore the associations between smoking and COVID-19 symptoms. SUBJECTS AND METHODS: A cross-sectional study using the Ministry of Public Health (MoPH), Qatar database was administered to a Qatari population with confirmed COVID-19 disease who filled in pre-defined phone-call questionnaire between 27th February 2020 and 31st December 2020. We analyzed 11,701 non-vaccinated COVID-19 individuals (2952 smokers and 8749 non-smokers) with confirmed RT-PCR test results. The association of smoking and the presence of symptoms as well as patient characteristics was calculated using Pearson’s Chi-square and Fisher’s exact tests, adjusting for potential covariates. RESULTS: Compared with the non-smokers, symptomatic COVID-19 infection is significantly higher in smokers. In addition, we found fever as the most common symptom developed in COVID-19 patients followed by cough, headache, muscle ache, and sore throat. As compared to other symptoms, association of smoking with chills and abdominal pain was less evident (P < 0.05 and P < 0.001, respectively). However, both groups showed similar rates of developing cough. CONCLUSION: In conclusion, smoking is associated with COVID-19 symptoms frequency in non-vaccinated patients; nevertheless, further investigations are necessary to understand the mechanism of this association which could generate new targets for the management of COVID-19 in smoker patients.

age of the study population was 34.5 years with the vast majority being males (97.3%). The most common nationality in this study was Indian which comprises around 25% of the population, followed by Qatari, Nepalese, and Bangladeshi. Diabetes and cardiovascular diseases were the most frequent comorbidities in the study population, each affecting around 6% of the patients. The rest of the comorbidities were rare. Four subjects from the smokers group underwent surgeries previously which was significantly higher than the non-smokers group, where only two had prior surgeries (P < 0.05) ( Table 1) .

As indicated in Table 2 , our data revealed that a significantly higher proportion of smokers developed symptomatic COVID-19 infection (75.3%) compared to the non-smokers (62.8%; P < 0.001), indicating that smokers have a risk ratio of 1.2 (95% confidence interval: 1.17-1.23) to develop symptoms related to COVID-19 infection when compared to nonsmokers ( Figure 1 ).

On the other hand, and as demonstrated in Figure 2 , the type of symptoms experienced in relation with smoking status show that fever is the most frequent symptom affecting 45% of confirmed COVID-19 cases, followed by cough, headache, muscle ache, and sore throat. Less frequent symptoms, present in less than 10% of patients, include chills, shortness of breath, diarrhoea, and abdominal pain. Smoking is associated with a significantly higher rate of developing all types of symptoms except cough, as both groups showed similar rates of developing cough (Table 2) . On the other hand, the association of smoking with chills and abdominal pain was less evident when compared to the rest of the symptoms (P < 0.05 and P < 0.001; respectively) ( Table 2 ).

In this investigation we explored for the first time the correlation between smoking and COVID-19 symptoms frequency in the population of Qatar. Our data revealed that current smoking is associated with a risk of developing symptoms 

suggestive of COVID-19, as well as a greater symptom burden, indicating an impact of smoking on COVID-19 disease frequency. Additionally, amongst patients positive for COVID-19, smokers had a higher symptom burden in comparison to non-smokers. In our cohort, 97% of COVID-19 patients are males and 3% are females, which concurs with recent studies of COVID-19 infection. [28] [29] [30] [31] Furthermore, in this study, the estimated median age for patients is 34 years which is concordant with previous studies among COVID-19 patients in other countries 32, 33 as well as in Qatar and Saudi Arabia. 29, 30, 34, 35 As compared to other parts of the world, COVID-19 is found to affect younger populations in the Gulf Region. 29, 30, 34 Such a trend is observed in our study, nevertheless, the age-groups effected with COVID-19 range from 15 to 87 years, indicating disease susceptibility across these ages. High infection and severity rates in adult patients are found to be associated with smoking, as seen in previous studies. 36, 37 Approximately 15% of COVID-19 patients investigated here exhibited various comorbidities as reported in previous studies. 27, 29, 38 In this study, we found that both smokers and non-smokers had diabetes (6%), followed by cardiovascular disease (6%) and asthma (1%). This is in concordance with other reports which showed diabetes and/or hypertension as the most common comorbidities. 27, 29, 32, 34, [39] [40] [41] However, our findings revealed that smoking had no significant association with diabetes and cardiovascular comorbidities. Along with cardiac and chronic respiratory diseases, lung and chronic kidney diseases are reported as risk factors associated with worse outcomes in COVID-19 patients. 42, 43 Similar to our data, various cohort studies revealed an association between smoking and COVID-19 disease comorbidity, incidence and mortality. 14, 16, 22, 27 In this context, smoking is known to damage the vascular endothelial, 44 a characteristic feature in COVID-19 pathophysiology. A meta-analysis of 13 published Chinese studies pointed out older age (age > 65 years), male gender, and smoking were risk factors for disease progression in COVID-19 patients. 45 On the other hand, a recent meta-analyses showed significant correlation between smoking and COVID-19 progression. 27, 46 Another meta-analysis based on 15 studies also reported concordant data where 22% of current and 46% of former smokers had severe COVID-19 complications. 14 A recent study by Almazeedi et al 47 was performed based on a cohort of 1096 COVID-19 patients in Kuwait and they reported that age > 50 years, smoking, elevated C-reactive protein (CRP) and prolactin levels as well as a quick sequential organ failure assessment (qSOFA) score greater than 0 as risk factors associated with COVID-19 severity. Likewise, a study on 10,713 COVID-19 patients from Brazil also reported smoking and pulmonary disease to augment the risk of COVID-19 severity. 48 In addition to studies carried out in larger cohorts, studies in small cohorts also showed similar results. 49, 50 Recently, Archie et al 51 postulated a plausible role of smoking on cerebrovascular and neurological dysfunction in COVID-19 patients. Recently, Jiménez-Ruiz 11 performed a systematic review and meta-analysis and reported that smoking is a risk factor for a severe COVID-19 infection with a plausibility of developing a more critical condition. Similarly, another investigation showed a clear association between smoking and disease severity, with approximately 3% of deceased patients being smokers. 52 Moreover, a metaanalysis that included 7 studies found that smokers had twice the risk of developing COVID-19 severity. 53 Although, smoking may not essentially elevate the risk of developing COVID-19, the underlying mechanisms involving the biological and inflammatory signaling pathways induced by COVID-19 infection can be severe for smokers. 21 Likewise, earlier research showed increased susceptibility to COVID-19 infection is attributed to the overexpression of one of the key SARS-CoV-2 receptors, angiotensin converting enzyme 2 (ACE2) receptor. 4, 17, 54 Smoking increases susceptibility to COVID-19 infection via the triggering of peripheral nicotinic acetylcholine receptors (nAChRs) present in various organ systems. 55 Nicotine disrupts homeostasis of the renin angiotensin system (RAS), and overexpresses the ACE/angiotensin (ANG)-II/ANG II type 1 receptor axis, resulting in cardiovascular and pulmonary diseases. 55 Hence, nicotine can affect the nAChRs and enhance the SARS-CoV-2 host entry. 56 Moreover, studies reported that smokers with diabetes, cardiovascular disease, COPD, asthma or cancer can enhance the expression pattern of ACE2; hence, they are more susceptible to develop COVID-19 infection and have worst prognosis. 57, 58 Diabetes can overexpress ACE2 expression via hyperinsulinemia along with other mechanisms. 59 During diabetes, the function of Treg cells is compromised and expression of tumor necrosis factor-alpha (TNF-α) is reduced, further enhancing infections. 59, 60 On the other hand, cardiovascular patients are also prone to COVID-19 disease severity. In hypertensive patients, ACE2 modulators (ACE1 inhibitors, ANG blockers, and thiazolidinediones) are often prescribed to treat hypertension and can overexpress ACE2; 39 a risk factor for the onset of COVID-19 disease. Likewise, the viral capsid of SARS-CoV-2 binds to the ACE2 surface and activates TMPRSS2, (Transmembrane serine protease 2, an androgen-responsive gene highly expressed in men), thus, increased TMPRSS2 expression in men increases their proneness to COVID-19 disease. 61 Furthermore, it has been demonstrated that cigarette exposure can increase the expression pattern of ACE2 and TMPRSS2 in patients with COPD and idiopathic pulmonary fibrosis (IPF); 17, [62] [63] [64] [65] [66] in this context, it is important to highlight that COPD is reported as a major risk factor for COVID-19 infection. 53, 67 Smokers suffering from cancer are also found to be at a higher risk of developing COVID-19 infection due compromised immunity, thus providing an effectual environment for viral replication. 68 On the contrary, while several studies reported an association between disease severity and smoking, 16, 22 few investigations found no difference or a negative correlation between smoking and COVID-19 severity. 23, 24 Moreover, a recent review reported that current smokers are at a comparatively lower risk of developing COVID-19 as compared to never smokers, however, these findings aim to analyse certain factors that could make the interpretation of these results more complex. 19 Hence, it is necessary to conduct interventional studies in the general population and in patients post-COVID-19 disease. In addition to investigations analysing the correlation between smoking and COVID-19 severity, reports on behavioural changes in tobacco consumption during the pandemic found varying data. While, in USA there was an increase by 41% in tobacco consumption during the onset of COVID-19, 69 in Italy, smokers had considered quitting. 70 However, the same study found that former smokers and never smokers wanted to start smoking. 70 In China and England as well, there was an increase in smoking among smokers and relapsed smoking habits among former 536 smokers. 71, 72 As of currently, both epidemiological/clinical evidence and in-silico findings indicate that COVID-19 infection is a nAChR disease that could be prevented and may be controlled by nicotine. 56, 73 Smoking was suggested to exert a protective measure as its nicotine acts as a nAChR agonist and competes with the SARS-COV-2 for the binding site, hence leading to a decline in accessible viral adhesion sites. 74 Nevertheless, the plausibility of nicotine displaying protective effect against COVID-19 can be partially masked by smoking-related toxicity. In addition, abrupt cessation of nicotine consumption when smokers are hospitalized need further validation in laboratory studies using nicotine-based pharmaceutical products. Considering the limited and contradicting past investigations available on this topic, we hypothesized a strong association of smoking with the risk of developing respiratory diseases. However, coughing, which is the major respiratory depression symptom was reported in both smokers and non-smokers nearly equally, with only a non-statistically significant difference of 1.4% more for smokers. Moreover, significant differences were reported in other symptoms such as fever, muscle ache, abdominal pain, diarrhoea, headaches, and shortness of breath, all of which are also symptoms of nicotinic overstimulation of the cholinergic system 75 which is activated by the nicotine in cigarettes and triggers COVID-19 disease. 76, 77 Although, our present study included a large sample size and points out a strong link between smoking and symptoms development among COVID-19 patients, there are several factors limiting the interpretation of our investigation. The present results remain limited by the available information. In particular, detailed data on possible sources of exposure to smoking are lacking. The data was self-reported by patients via phone-call based forms. The patients reported their symptoms through this form. Additionally, there was no classification based on the number of packs smoked per day. Thus, heavy smokers and light smokers were grouped together. Moreover, patients who reported as non-smokers are assumed to have no history of smoking and thus, we believe that further studies are needed to investigative the consequences and underlying mechanisms of smoking and its association with COVID-19 infection and its frequency in patients. In addition to cigarette smoking, effects of waterpipe and electronic cigarette use on COVID-19 transmission, clinical progression and frequency of COVID-19 should be further studied. Lastly, the association between COPD frequency and COVID-19 should be also analysed.

In conclusion, our present study demonstrates an association between smoking and COVID-19 symptoms frequency in non-vaccinated patients. While we believe that further studies in a larger cohort are required to clearly determine the association between smoking and COVID-19 symptoms which can help in controlling COVID-19 induced morbidity and mortality especially in smoker patients. Nevertheless, and based on our present study it is evident that discontinuing of smoking practices should be contemplated as a part of the strategies to address COVID-19 infection management in the international arena, as smoking increases both the likelihood of symptomatic disease and the frequency of disease.

Patient consent was waived as this was a matched cross-sectional study conducted using the Ministry of Public Health (MoPH), Qatar database. The study was conducted according to the guidelines of the Declaration of Helsinki, and approved by the Institutional Review Board (or Ethics Committee) of Ministry of Public Health (IRB: ERC-826-3-2020).

Aerosol and surface stability of SARS-CoV-2 as compared with SARS-CoV-1

Di Napoli R. Features, evaluation and treatment coronavirus (COVID-19). In: Statpearls [Internet

Unique epidemiological and clinical features of the emerging 2019 novel coronavirus pneumonia (COVID-19) implicate special control measures

Smoking upregulates angiotensin-converting enzyme-2 receptor: a potential adhesion site for novel coronavirus SARS-CoV-2 (Covid-19)

Coronavirus (COVID-19): a review of clinical features, diagnosis, and treatment

Tobacco smoke induces and alters immune responses in the lung triggering inflammation, allergy, asthma and other lung diseases: a mechanistic review

Tobacco use increases susceptibility to bacterial infection

Cigarette smoking increases the risk for subgingival infection with periodontal pathogens

Cigarette smoking and infection

Dysfunctional immunity and microbial adhesion molecules in smoking-induced pneumonia

COVID-19 and smoking: a systematic review and meta-analysis of the evidence

Smoking and influenza-associated morbidity and mortality: a systematic review and meta-analysis

Cigarette smoking and the occurrence of influenza-systematic review

Prevalence, severity and mortality associated with COPD and smoking in patients with COVID-19: a rapid systematic review and meta-analysis

Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan

Clinical characteristics of coronavirus disease 2019 in China

Cigarette smoke exposure and inflammatory signaling increase the expression of the SARS-CoV-2 receptor ACE2 in the respiratory tract

COVID-19 and smoking: a systematic review of the evidence

The association of smoking status with SARS-CoV-2 infection, hospitalization and mortality from COVID-19: a living rapid evidence review with Bayesian meta-analyses (version 7)

COVID-19 and the nicotinic cholinergic system

Smoking, ACE-2, and COVID-19: ongoing controversies

Analysis of factors associated with disease outcomes in hospitalized patients with 2019 novel coronavirus disease

Retrospective study on the epidemiological characteristics of 139 patients with novel coronavirus pneumonia on the effects of severity

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

Characteristics associated with hospitalization among patients with COVID-19 -metropolitan

Impact of smoking status on disease severity and mortality of hospitalized patients with COVID-19 infection: a systematic review and meta-analysis

Association of smoking history with severe and critical outcomes in COVID-19 patients: a systemic review and meta-analysis

High mortality rate in adult COVID-19 inpatients in Eastern Sudan: a Retrospective Study

Comorbidities and risk factors for severe outcomes in COVID-19 patients in Saudi Arabia: a Retrospective Cohort Study

Epidemiological investigation of the first 5685 cases of SARS-CoV-2 infection in Qatar

Characterization and clinical course of 1000 patients with coronavirus disease 2019 in New York: retrospective case series

COVID-19 with different severities: a multicenter study of clinical features

Clinical features of COVID-19 in elderly patients: a comparison with young and middle-aged patients

Clinical characteristics of COVID-19 in Saudi Arabia: a national retrospective study

Epidemiology of COVID-19 in the Kingdom of Saudi Arabia: an Ecological Study. Front Public Health

SARS-CoV-2 and COVID-19 in older adults: what we may expect regarding pathogenesis, immune responses, and outcomes

Understanding pathophysiology of hemostasis disorders in critically ill patients with COVID-19

Clinical characteristics of asymptomatic and symptomatic COVID-19 patients in the Eastern Province of Saudi Arabia

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Prevalence of comorbidities in COVID-19 patients: a systematic review and meta-analysis

Clinical characteristics and outcomes of the first 63 adult patients hospitalized with COVID-19: an experience from Oman

Risk factors associated with worse outcomes in COVID-19: a retrospective study in Saudi Arabia

Clinical characteristics and in-hospital mortality of COVID-19 adult patients in Saudi Arabia

Smoking and cardiovascular disease: mechanisms of endothelial dysfunction and early atherogenesis

Risk factors of critical & mortal COVID-19 cases: a systematic literature review and meta-analysis

Smoking is associated with COVID-19 progression: a meta-analysis

Characteristics, risk factors and outcomes among the first consecutive 1096 patients diagnosed with COVID-19 in Kuwait

Risk factors for hospitalization and mortality due to COVID-19 in Espírito Santo State, Brazil

Prediction model and risk scores of ICU admission and mortality in COVID-19

Association between smoking and COVID-19 severity: evidence from Bangladesh

Cerebrovascular and neurological dysfunction under the threat of COVID-19: is there a comorbid role for smoking and vaping?

The clinical and demographical profile of Coronavirus illness: the tale of Tablighi Jamaat and Zaireen in Quarantine/Isolation center at Sukkur and Hyderabad

The impact of COPD and smoking history on the severity of COVID-19: a systemic review and meta-analysis

ACE-2 expression in the small airway epithelia of smokers and COPD patients: implications for COVID-19

Nicotine and the renin-angiotensin system

A nicotinic hypothesis for Covid-19 with preventive and therapeutic implications

Role of angiotensin-converting enzyme (ACE) and ACE2 in a rat model of smoke inhalation induced acute respiratory distress syndrome

Distribution of ACE2, CD147, CD26, and other SARS-CoV-2 associated molecules in tissues and immune cells in health and in asthma, COPD, obesity, hypertension, and COVID-19 risk factors

Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China

Outcomes in patients with hyperglycemia affected by COVID-19: can we do more on glycemic control? Diabetes Care

ACE2 and TMPRSS2 variants and expression as candidates to sex and country differences in COVID-19 severity in Italy

Airways expression of SARS-CoV-2 receptor, ACE2, and TMPRSS2 is lower in children than adults and increases with smoking and COPD

Multi-level immune response network in mild-moderate Chronic Obstructive Pulmonary Disease (COPD)

Comprehensive analysis of transcriptome sequencing data in the lung tissues of COPD subjects

Transcriptional regulatory model of fibrosis progression in the human lung

Up-regulation and profibrotic role of osteopontin in human idiopathic pulmonary fibrosis

Chronic obstructive pulmonary disease is associated with severe coronavirus disease 2019 (COVID-19)

Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study

Tobacco quit intentions and behaviors among cigar smokers in the United States in response to COVID-19

Smoking behavior and psychological dynamics during COVID-19 social distancing and stay-at-home policies: a survey

Brief report: increased addictive internet and substance use behavior during the COVID-19 pandemic in China

COVID-19: risk of increase in smoking rates among England's 6 million smokers and relapse among England's 11 million exsmokers

The effect of smoking on COVID-19 severity: a systematic review and meta-analysis

Current smoking, former smoking, and adverse outcome among hospitalized COVID-19 patients: a systematic review and meta-analysis

The local side effects of transdermally absorbed nicotine

COVID-19 and smoking

Nicotinic cholinergic system and COVID-19: in silico evaluation of nicotinic acetylcholine receptor agonists as potential therapeutic interventions

This includes studies and reviews conducted by multidisciplinary teams as well as research which evaluates the results or conduct of such teams or healthcare processes in general. The journal covers a very wide range of areas and welcomes submissions from practitioners at all levels, from all over the world. The manuscript management system is completely online and includes a very quick and fair peer-review system

We would like to thank Qatar's Ministry of Public Health for providing the data used in this study. Also, we would like to thank the Department of Population Medicine at College of Medicine, Qatar University for their support provided throughout the study.

This research received no external funding. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results. 

The authors report no conflicts of interest in this work.